980
Views
0
CrossRef citations to date
0
Altmetric
Articles

Global dynamics for a model of amyloid fibril formation in pancreatic islet beta cells subjected to a therapy

, &
Pages 162-186 | Received 27 Mar 2019, Accepted 11 Feb 2020, Published online: 04 Mar 2020

Abstract

Amyloid polypeptide (IAPP) fibril formation is the main cause of type II diabetes mellitus (T2DM) disease and cardiovascular disease (CVD). Therefore, implementing therapeutic interventions strategies to control IAPP fibril formation plays a crucial role in preventing and managing T2DM disease and CVD. For this purpose, in this paper, we make use of a mathematical model to investigate the effects of drug therapy on the dynamics of amyloid fibril formation (or amyloid plaques). The model is a hybrid system of differential equations consisting of ODEs and (hyperbolic) PDE. The (global) stability analysis is established through the construction of suitable Lyapunov functionals and application of Lasalle's invariance principle. Moreover, stability of the disease steady state is fully determined by a threshold condition, which is based on the total population of IAPP polymers.

2010 Mathematics Subject Classifications:

1. Introduction

Amyloid plaques are widely regarded as a pathogenic factor of type II diabetes mellitus (T2DM) disease, which is initially caused by a state of insulin resistance before advancing to the state of insulin dependency. These amyloid plaques arise from misfolding of a (37 amino acid) hormone called islet amyloid polypeptide (IAPP), also known as amylin, within and around the pancreatic islet β-cells that co-secrete both insulin and IAPP [Citation4] and it is proven in [Citation2] that increasing insulin in the state of insulin resistance causes an increase of IAPP secretion, as a result of their co-regulation. The occurrence of amyloid deposits is done through a process known as nucleated polymerization, detailed in [Citation16,Citation21], by which several thousands of IAPP monomer units are attached by aggregation, in a string like manner, to produce a polymer (or an oligomer) called IAPP fibril formation also known as amyloid plaque. Since IAPP units are misfolded with the IAPP fibril formation, this results in structural and functional changes of IAPP units. As a consequence, the IAPP fibril formation becomes dysfunctional within and around the pancreatic islet β-cells.

Amyloid plaques (IAPP fibril formation) are accountable for loss in β-cell mass in patients with T2DM disease [Citation8]. In addition to this, numerous in vitro investigations have proven that amyloid plaques occurring around (outside) β-cells can lead to their extinction through the formation of reactive oxygen species, mitochondrial dysfunction, chromatin condensation, and apoptotic mechanisms [Citation6]. We refer to [Citation6,Citation9,Citation10] and the references therein for more detailed information about the biological background for the origin and development of T2DM. It is reported in [Citation15] that there exists a strong correlation between the degree of T2DM disease seriousness and the amount of amyloid plaque deposited.

Therapeutic interventions in form of drugs (such as beta-sheet blockers, herparin sulphate proteoglycan derivatives, serum amyloid P inhibitors) or vaccination policies (see [Citation7,Citation9]) can be used to block the IAPP fibril formation and therefore prevent its damaging impacts on pancreatic islet β-cells and insulin-production capacity. It is reported in [Citation14] that amyloid plaques are also regarded as a pathogenic factor of hypertension and therefore, due to their dissimilar metabolic and structural impacts, numerous classes of anti-hypertensive drugs prevent the IAPP fibril formation, hence cannot give rise to the T2DM disease. Thus, T2DM disease and hypertension are both accountable for significant widened cardiovascular disease (CVD) morbidity and mortality [Citation7]. With regards to anti-diabetic drugs, it also important to highlight that there is controversy related to the treatment of diabetes, and the connection, with Alzheimer's disease (AD) as reported below. In their previous study, Kim et al. exhibited evidence that the inflammation-related S100A9 gene is considerably upregulated in the brains of AD animal models and human AD patients. This was also supported by some experiments which showed that knockdown of S100A9 expression ameliorates cognition in AD model mice (Tg2576), and these animals present reduced amyloid plaque formation. In their subsequent study [Citation12], Kim et al. developed a novel transgenic animal model of AD by crossbreeding the Tg2576 mouse with the S100A9 knockout (KO) mouse. They notice that S100A9KO/Tg2576 (KO/Tg) mice displayed an increased spatial reference memory in the Morris water maze task and Y-maze task as well as decreased amyloid beta peptide (Aβ) neuropathology because of reduced levels of Aβ, C-terminal fragments of amyloid precursor protein (APP-CT) and phosphorylated TAU and increased expression of anti-inflammatory Interleukins-10 (IL-10) and also decreased expression of inflammatory Interleukins-6 (IL-6) and tumour neurosis factor (TNF)-α when compared with age-matched S100A9WT/Tg2576 (WT/Tg) mice. Overall, these results suggest that S100A9 is responsible for the neurodegeneration and cognitive deficits in Tg2576 mice. The mechanism of S100A9 is able to coincide with the inflammatory process. The outcomes from this research study reveal that knockout of S100A9 is a potential target for the pharmacological therapy of AD. However, contrary to the previous authors, some studies have indicated that insulin resistance (IR) is a potential target for the pharmacological therapy of both AD and diabetes. The latter statement is supported by the following findings. In the review [Citation3], the aim of the study is to discuss the existing evidence supporting the idea that brain insulin resistance and altered glucose metabolism play a crucial role in the pathogenesis of late-onset Azheimer disease (LOAD) and AD treatment approaches targeting insulin signalling using anti-diabetic drugs and mTOR inhibitors. The authors investigated some potential pharmacological approaches for LOAD treatment related with the regulation of insulin metabolism, using anti-diabetic drugs (such as pioglitazone, intranasal insulin, NMDAR antagonists such as memantine and inhibitors of mTOR activity such as rapamycin and its derivatives (rapalogs)), and the findings give support to the continued investigation on potential stimulation of insulin receptor as a therapy for LOAD for intranasal insulin treatments and to the therapeutic potentials of temsirolimus in preclinical models of AD. However, although preclinical data give support to the potential beneficial effects of pioglitazone in AD, clinical data reported until now shows conflicting results regarding efficacy due to the many limitations of these trials and thus, further clinical trials on the potential use of pioglitazone for the treatment of LOAD are necessary. In the recent published review [Citation11], it is stated that clinical studies and preclinical data in the last decade proved that AD and diabetes mellitus share a pathophysiological pathway, indicating that insulin resistance, oxidative stress and inflammatory response would increase the risks of developing AD in diabetic patients. This review presents briefly the aetiology of AD and diabetes, discusses the feasible theories about the interplaying risk factors and the mechanism of action of anti-diabetic medications recommended for the treatment of AD. Authors used some classes of anti-diabetic drugs (including insulin, thiazolidinediones, sulfonylurea, metformin, amylin analogue) as potential treatments for AD and the findings confirm that the anti-diabetic medications can actually exert an effect on brain functions including memory, cognition and attention. Intranasal administration was considered as the best route for insulin delivery into the brain as it traverses directly into the blood-brain barrier (BBB). Metformin is considered one of the most important oral medications given in diabetic patients, except for those who suffer from lactic acidosis, and has been studied extensively. There are many clinical studies tend to support its efficacy in cognitive enhancement. Despite controversial findings, it is agreed that the earlier the stage of AD, the more chance for anti-diabetics to have a positive effect on brain functions. The authors also suggested that more clinical trials and investigations should be done in this field to limit the progression of AD, find better treatment outcomes and increase the quality of life in AD patients.

In this paper we consider an existing model, describing the nucleated polymerization's dynamics of human amyloid polypeptide (HIAPP or IAPP) within the pancreatic islet β-cells under the impacts of therapeutic interventions, as formulated in [Citation15]. The model is made up of the rates of changes of the IAPP monomers population size, IAPP polymers of length x population size and amount drug in the system. This is a hybrid system of non-linear coupled ordinary and partial differential equations, where M(t), p(x,t) and D(t) denote the IAPP monomers population size, the IAPP polymers of length x population density and the amount of drug in the system, respectively, at time t. The governing equations of the model are given by (1) ddtM(t)=AgM(t)rM(t)x0p(x,t)dx+20x0xx0b(y)f(x,y)p(y,t)dydxtp(x,t)=rM(t)xp(x,t)(m(x)+b(x)+k2D(t))p(x,t)+2xb(y)f(x,y)p(y,t)dyddtD(t)=k0D(t)+k1D(t)x0p(x,t)dx,(1) with initial conditions (2) M(0)=M0,D(0)=D0,p(x,0)=p0(x),(x0<x<),(2) and boundary conditions (3) p(x0,t)=0,t0,(3) where M0 and p0(x) are IAPP monomers population and IAPP polymers of length x initial sizes, D0 is an initial amount of drug in the system and x0 is the critical length of the IAPP polymer below which the IAPP polymer breaks down into normal IAPP monomers. Parameters in (Equation1) are all positive (constant or function) which account for the following:

  1. constant rate of production of IAPP monomers in the pancreatic beta cells

  2. constant rate of degradation of IAPP monomers due to metabolism processes

  3. constant polymerization rate (also known as the conversion rate of IAPP monomers to IAPP polymers)

  4. rate at which the drug is degraded from the system due to metabolic processes

  5. rate at which the drug increases in the system

  6. rate at which the polymer population reduces due to the presence of the drug

  7. binary splitting rate of the IAPP polymers of length x

  8. degradation rate of the IAPP polymers due to metabolism

  9. probability density function that a polymer of length y splits into two polymers of lengths x and yx.

On the right-hand side of the first equation in (Equation1), the last term accounts for the number of IAPP monomers resulting from the splitting of an IAPP polymer which also produces at least one IAPP polymer of length lesser than x0. It is assumed that such an IAPP polymer dissociates from IAPP monomers. The factor 2 in this term explains the binary splitting of an IAPP polymer of length x into two polymers whenever x>x0. It is also assumed that the length of IAPP polymers picks up continuous values for mathematical analysis purposes. Moreover, on the right-hand side of the second equation in (Equation1), the first term (the transport term) and the last term represent, respectively, the loss in the amount of IAPP polymers of length x as a result of lengthening and the gain of IAPP polymers of length x due to splitting of lengthy polymers.

The total amount of IAPP polymers and the total amount of IAPP monomers in IAPP polymers, of length x, will be denoted by the time functions P(t)=x0p(x,t)dx,andQ(t)=x0xp(x,t)dx, respectively. Clearly, for any t0, (4) P(t)<Q(t).(4) In [Citation15] Murali and Raman made use of the following assumptions: m(x)=m,b(x)=bx,andf(x,y)={1yify>x00ifyx0oryx for simplifying the model (Equation1)–(Equation3) into a model consisting of a system of ordinary differential equations given by (5) ddtM(t)=AgM(t)+bx02P(t)rM(t)P(t)ddtP(t)=mP(t)+bQ(t)2bx0P(t)k2D(t)P(t)ddtQ(t)=mQ(t)bx02P(t)k2D(t)Q(t)+rM(t)P(t)ddtD(t)=k0D(t)+k1D(t)P(t)(5) subject to initial conditions (6) M(0)=M0,P(0)=P0,Q(0)=Q0,D(0)=D0,(6) where M0,P0,Q0,D00. An asymptotic behaviour of the system of equations (Equation5)–(Equation6) is carried out under the above-mentioned assumptions. A disease-free state equilibrium, E1=(M~,P~,Q~,D~)=(A/g,0,0,0), and a disease state equilibrium, E2=(M´,P´,Q´,D´), where M´=(bx0+m)2br,P´=brAg(bx0+m)2mr(2bx0+m),Q´=brAg(bx0+m)2mbr,D´=0, with brA>g(bx0+m)2, of the system of equations (Equation5)–(Equation6) were found after nullifying therapeutic interventions effects; while a coexistence state equilibrium, E3=(M,P,Q,D), where M=A+bx02Pg+rP,P=k0k1),Q=(rMbx02)Pm+k2D,D=brM(m+bx0)k2, with rAM>max{bx02,b1(bx0+m)2}, of the system of equations (Equation5)–(Equation6) is found after taking into account the therapeutic interventions. The local stability of equilibria is proven by the mean of the Routh-Hurwitz criterion and revealed that E1 (respectively E2) is locally asymptotically stable if and only if brA<g(m+bx0)2 (respectively brA>g(m+bx0)2 and P´<k0/k1) and E3 is locally asymptotically stable if some conditions (as given in [Citation15, p. 6]) are satisfied. Next, Murali and Raman used some numerical stimulations based on the system of equations (Equation5)–(Equation6) to confirm the results from the theoretical analysis.

In contrast to the results from Murali and Raman in [Citation15] and from other authors in references therein, here we consider arbitrary (bounded or unbounded) functions b() and m(). Furthermore, for the sake of handling the hybrid system of equations (Equation1)–(Equation3), we make the following assumptions:

  1. k1=k2,

  2. functions b() and m() satisfy max{(x+4)b(x),rA/g}<m(x), where 1<m(x)+b(x), for any xx0,

  3. f(x,y) satisfies the natural constraints, see [Citation17,Citation19], (7) f(x,y)=f(yx,y),y>x0,0<x<y,(7) which accounts for the binary splitting of the IAPP polymers, and (8) 0yf(x,y)dx=1,y>x0.(8) These two constraints, namely (Equation7) and (Equation8) yields (9) 20yxf(x,y)dx=y,y>x0,(9) i.e. there is the conservation of number of monomers during the splitting process.

The problem consisting of Equations (Equation1)–(Equation3) subjected to assumptions A1A3 is regarded as novel and have not yet been investigated to our best knowledge. Such a problem is mathematically challenging but allows to provide some relevant features of the model. We make use of the mathematical tool developed in [Citation13] to carry out the steady states and stability analysis of Equations (Equation1)–(Equation3). The rest of the paper is structured as follows. Section 2 deals with some preliminary results and more importantly the existence result of global attractors for the continuous semi-flow defined by the system of equations (Equation1)–(Equation3). The steady states of the system of equations (Equation1)–(Equation3) are computed in Section 3. Three equilibria are obtained: a disease-free state equilibrium, a disease state equilibrium and a coexistence state equilibrium. The next section, namely Section 4, is devoted to the uniform persistence of the coexistence state equilibrium. Sections 5 and 6 deal, respectively, with local and global stability analysis of the disease-free state equilibrium and disease state equilibrium.

2. Preliminaries

Let X1 be defined by X1=L1([x0,),xdx)={ϕ:ϕ1=x0x|ϕ(x)|dx}. We consider the Banach space X=R×X1×R endowed with the norm (u,ϕ,v)X=|u|+ϕ1+|v|, for any (u,ϕ,v)X. Let us denote by X+ the positive cone of the Banach space X such that X+=R+×X1,+×R+, where X1,+=L+1([x0,),xdx)

For any initial value X0=(M0,p0(),D0)X+ satisfying the following condition p0(0)=0, the system of equations (Equation1)–(Equation3) is well-posed. Indeed, the well-posedness of the system of equations (Equation1)–(Equation3), without therapeutic interventions (that is, D()0), is established in [Citation17], where the existence and uniqueness of global classical solutions for bounded functions b() and m() and the existence and uniqueness of global weak solutions for unbounded functions b() and m() are shown. So, this result can easily be extended to the solvability of the system of equations (Equation1)–(Equation3) with therapeutic interventions. So, we obtain a continuous semi-flow Φ:R+×X+X+ defined by the system of equations (Equation1)–(Equation3) so that (10) Φ(t,X0)=Φt(X0)=(M(t),p(,t),D(t)),tR+,X0X+.(10)

Since the components of Φt(X0) are positive, using the above notation, we obtain (11) Φt(X0)X=M(t)+p(,t)1+D(t).(11) Differentiating (Equation11) with respect to t yields (12) ddtΦt(X0)X=ddtM(t)+ddtp(,t)1+ddtD(t).(12) Next, we show that (13) ddtp(,t)1=ddtx0xp(x,t)dx=x0xtp(x,t)dx.(13) Substituting the second equation of (Equation1) into (Equation13) leads to (14) ddtp(,t)1=x0x(rM(t)tp(x,t)(m(x)+b(x)+k2D(t))p(x,t))dx+2x0xxb(y)f(x,y)p(y,t)dydx.(14) Expanding the integrand of the first integral, changing the order of integration of the last integral in (Equation14) and using assumption A1, we get (15) ddtp(,t)1=rM(t)x0xtp(x,t)dxx0x(m(x)+b(x))p(x,t)dxk1D(t)x0xp(x,t)dx+x0(2x0yxf(x,y)dx)b(y)p(y,t)dy.(15) Combining Equation (Equation15), the first and third equations of (Equation1), we get (16) ddt(M(t)+p(,t)1+D(t))=A(gM(t)+rgAp(,t)1+k0D(t))k1(Q(t)P(t))D(t).(16) Let η be such that (17) rA<ηinf{g,k0,rgA}.(17) Using (Equation4), we have (18) ddt(M(t)+p(,t)1+D(t))Aη(M(t)+p(,t)1+D(t)),(18) that is, (d/dt)Φt(X0)XAηΦt(X0)X. Thus, we obtain (19) Φt(X0)XAηeηt(AηX0X),whereΦ0(X0)X=X0X.(19) Let Γ be the state space of (Equation1), defined by Γ={(u,ϕ,v)X+:(u,ϕ,v)XAη}. From (Equation19), we get Φt(X0)XA/η for any t0, whenever X0Γ. Moreover, limsuptΦt(X0)XA/η for any X0X+. Then, we obtain the following result.

Lemma 2.1

The set Γ is positively invariant for Φ; that is, Φt(X0)Γ,t0, X0Γ, t0, X0Γ. Moreover, Φ is point dissipative.

As we aim to make use of the Lasalle's Invariance Principle, we are required to establish the relative compactness of the orbit {Φt(X0):t0} in X+ due to the infinite-dimensional Banach space X. This is done as in [Citation13] by introducing two operators Θ and Ψ, (Θ,Ψ:R+×X+X+), defined by (20) Θt(X0)=(0,p(x,t),0)andΨt(X0)=(M(t),0,D(t)),(20) where Θ(t,X0)=Θt(X0) and Ψ(t,X0)=Ψt(X0), so that (21) Φt(X0)=Θt(X0)+Ψt(X0),foranyt0,(21) and by obtaining, from the proof of [Citation20, Proposition 3.13] and Lemma 2.1, the result below.

Theorem 2.2

For X0Γ, the orbit {Φt(X0):t0} has a compact closure in X+ if the following conditions are satisfied.

  1. There exists a function Δ:R+×R+R+ such that for any r>0, limtΔ(t,r)=0, and if X0Γ with X0Xr, then Θt(X0)XΔ(t,r) for any t0.

  2. For any t0, Ψt() maps any bounded sets of Γ into a set with compact closure in X+.

Conditions (i) and (ii) of Theorem 2.2 are verified through the following lemmas.

Lemma 2.3

For δ>0, let Δ(t,δ)=eηtδ. Then limtΔ(t,δ)=0. Then (i) of Theorem 2.2 holds.

Proof.

We have limtΔ(t,δ)=0. We choose the initial condition X0Γ such that X0Xr. For t0, we have Θt(X0)X=|0|+p(,t)1+|0|=p(,t)1. Using (Equation4), (Equation9), (Equation15), (Equation17), assumptions A1 and A2, we have (22) ddtp(,t)1rηAp(,t)1ηx0xm(x)p(x,t)dx=(rηAη)p(,t)1,(22) and hence p(,t)1e((r/η)Aη)p0()1e((r/η)Aη)t(|M0|+p0()1+|D0|); that is, p(,t)1e((r/η)Aη)tX0X. Therefore, we get Θt(X0)Xeηtδ=Δ(t,δ), where δ=e(r/η)AtX0XX0X. Moreover, since (r/η)Aη=(rA+η)(rAη)/η, using (Equation17), it is easy to see that Δ(t,δ)0 as t. This completes the proof.

Lemma 2.4

For t0, Ψt() maps any bounded set of Γ into a set with a compact closure in X+.

Proof.

Since M(t) and D(t) remain in the compact set [0,A/η] by Lemma 2.1, Ψt():ΓΨt(Γ), where (23) Ψt(Γ)={Ψt(X0)X+:Ψt(X0)XAη}.(23) We clearly see, from (Equation23), that the set Ψt(Γ) is bounded. To establish the closedness of the set Ψt(Γ), we consider α and σ such that α=limtM(t) and σ=limtD(t). By the continuity of the norm X, we have (α,0,σ)XA/η, that is limtΨt(X0)Ψt(Γ) for all X0Γ. Hence, the set Ψt(Γ) is closed.

By definition, Ψt(Γ)¯ is the smallest closed set that contains Ψt(Γ), that is Ψt(Γ)Ψt(Γ)¯. Moreover, Ψt(Γ)¯ is also a closed set that contains Ψt(Γ). So, Ψt(Γ)¯Ψt(Γ). Therefore, Ψt(Γ)¯=Ψt(Γ).

By way of contradiction, suppose that Ψt(Γ)¯ is not compact in X+, that is Ψt(Γ)¯ is not totally bounded, since Ψt(Γ)¯ is complete as a closed set of a Banach space X, which is a complete space. This means that for some positive ε and for any finite KΨt(Γ)¯ we can find UΨt(Γ)¯ such that VUX+ and VUX>ϵ for every VK. Let (Vn) be a sequence of points in K, that is VnXA/η for any nN. Thus VnUX+ and VnUX>ϵ for any nN. It follows that VnXVnUX, and hence VnX>ϵ for any nN. Choosing ϵ=A/η yields a contradiction and therefore Ψt(Γ)¯ is a totally bounded and complete set. Hence, Ψt(Γ)¯ is a compact set in X+.

Therefore, From Lemma 2.1 and Theorem 2.2, the existence result of global attractors (see [Citation5]) follows.

Theorem 2.5

The semi-flow {Φt(X0):t0} has a global attractor in X+, which attracts any bounded subset of X+.

3. Equilibria

The equilibria of the system (Equation1) are given by the following equations (24) 0=A(g+rP)M+20x0xx0b(y)f(x,y)p(y)dydx0=rMdpdx(x)(m(x)+b(x)+k2D)p(x)+2xb(y)f(x,y)p(y)dy0=(k0+k1P)D,(24) where P=x0p(x)dx. From the last equation in (Equation24), it follows that D = 0 or P=k0/k1. If D = 0, the system (Equation24) reduces to (25) 0=A(g+rP)M+20x0xx0b(y)f(x,y)p(y)dydx0=rMdpdx(x)(m(x)+b(x))p(x)+2xb(y)f(x,y)p(y)dy.(25) By assuming p(x)=0 in (Equation25), we obtain the disease-free steady state E0 of the system (Equation1) given by E0=(M0,p0(x),D0), where M0=A/g,p0(x)=0,D0=0. However, by assuming p(x)0 in (Equation25), from the last equation in (Equation25), we have (26) 2xb(y)f(x,y)p(y)dy=rMdpdx(x)+(m(x)+b(x))p(x)(26) and we substitute (Equation26) into the first equation of (Equation25) to obtain A(g+rP)M+20x0xx0xb(y)f(x,y)p(y)dydx=0, that is A(g+rP)M20x0xxx0b(y)f(x,y)p(y)dydx=0. By changing the order of integration in the latter equation, we have A(g+rP)M0x0(20yxf(x,y)dx)b(y)p(y)dy=0. Using (Equation9), the latter equation yields A(g+rP)M0x0yb(y)p(y)dy=0, which implies A(g+rP)M=0. Thus, a disease steady state E of the system (Equation1) is given by E=(M,p(x),D), where M=A/(g+rP),D=0 and p(x) is the solution of the non-linear ordinary differential equation dpdx(x)+m(x)b(x)rM0p(x)=p(x)Ax0p(x)dx. If P=k0/k1, the system (Equation24) reduces to (27) 0=A(g+rk0k1)M+20x0xx0b(y)f(x,y)p(y)dydx0=rMdpdx(x)(m(x)+b(x)+k2D)p(x)+2xb(y)f(x,y)p(y)dy.(27)

From the last equation of (Equation27), we have (28) 2xb(y)f(x,y)p(y)dy=rMdpdx(x)+(m(x)+b(x)+k2D)p(x)(28) and the first equation of (Equation27) is equivalent to (29) 0=A(g+rk0k1)M20x0xxx0b(y)f(x,y)p(y)dydx+20x0xxb(y)f(x,y)p(y)dydx.(29) Substituting (Equation28) into (Equation29) leads to 0=A(g+rk0k1)M20x0xxx0b(y)f(x,y)p(y)dydx and after changing the order of integration and using (Equation9) in the latter equation, we get 0=A(g+rk0k1)M0x0yb(y)p(y)dy, which reduces to 0=A(g+rk0k1)M. Thus, a coexistence steady state E˘ of the system is given by E˘=(M˘,p˘(x),D˘), where M˘=k1A/(k0r+k1g),D˘0 and p˘(x) is the solution of the linear ordinary differential equation (30) dpdx(x)=k0r+k1gk1Ar(m(x)b(x)+k2D)p(x),(30) where D=D˘ and k2=k1 (see A1). Defining x¯0=inf{x|p(x)0forx>x0} and integrating (Equation30) over [x¯0,x] leads to p(x)=p(x¯0)Ω(x), where Ω(x)=exp{k0r+k1gk1rA(k1D˘(xx¯0)+x¯0x(m(s)b(s))ds)}. Thus, the equation x0p(x)dx=k0k1 yields p(x¯0)=k0/k11/x0Ω(x)dx and hence p(x)=k0/k1Ω(x)/x0Ω(x)dx, that is p˘(x)=k0/k1Ω(x)/x0Ω(x)dx.

4. Uniform persistence

In this section, we investigate the uniform persistence of the system (Equation1) at the disease state equilibrium E, that is under the condition (31) k1k0x0p(x)dx<1.(31) To do this, we consider a function ρ:XR+ defined by (32) ρ(u,ζ,v)=k1k0x0ζ(x)dx,where(u,ζ,v)X+.(32) Let X0 be a set defined by X0={X0X+:ρ(Φt0(X0))>0forsomet00} so that Φt(X0)E0 as t whenever X0X+X0.

Definition 4.1

see [Citation18, p. 61]

Φ is uniformly weakly ρ-persistent (respectively, uniformly (strongly) ρ-persistent) if there exists a positive ε, not depending of initial conditions, so that limsuptρ(Φt(X0))>ϵ(respectively,liminftρ(Φt(X0))>ϵ) for any X0X+.

Theorem 4.2

Let (Equation31) be satisfied. Then Φ is uniformly (strongly) ρ-persistent.

Proof.

By way of contradiction, for all ϵ>0 there exists XϵX0 such that liminftρ(Φt(Xϵ))ϵ. In particular, there exists Xϵ0X0 such that (33) liminftρ(Φt(Xϵ0))ϵ0,(33) where 0<ϵ0<1. Choosing ϵ0=k1A/k0η and using (Equation4) yields (34) k1k0x0pϵ0(x)dx<k1k0x0xpϵ0(x)dx.(34) It follows that (35) k1k0x0pϵ0(x)dx<k1k0pϵ0(,t)p()1+k1k0x0p(x)dx,(35) and hence (36) ρ(Φt(Xϵ0))<k1k0Φt(Xϵ0)EX+k1k0x0p(x)dx.(36) Since Φt(X0)E˘Γ, we can make use of (Equation31) so that (37) ρ(Φt(Xϵ0))<k1Ak0η+1,(37) that is, (38) ρ(Φt(Xϵ0))<ϵ0+1,forallt0.(38) Therefore (39) liminftρ(Φt(Xϵ0))limsuptρ(Φt(Xϵ0))<ϵ0+1.(39) This contradicts (Equation33) and thus complete the proof.

5. Local stability of equilibria

The local stability for equilibria of the system (Equation1) will be investigated through its linearization around each equilibrium, see [Citation13]. To achieve this, we will perturb the equilibria as follows. For the disease-free steady state E0, we introduce new functions u, v(x,) and w such that u(t)=M(t)M0,v(x,t)=p(x,t),w(t)=D(t). Differentiating functions u, v(x,) and w with respect to time t, making use of equations in (Equation1) and omitting terms of order higher than or equal to two, lead to the following system (40) dudt(t)=gu(t)rM0x0v(x,t)dx+20x0xx0b(y)f(x,y)v(y,t)dydxvt(x,t)=rM0vx(x,t)(m(x)+b(x))v(x,t)+2xb(y)f(x,y)v(y,t)dydwdt(t)=k0w(t).(40) In order to derive the spectrum of the linear operator associated to the linearized system (Equation40), we consider exponential solutions of the form (41) u(t)=u¯eλt,v(x,t)=v¯(x)eλt,w(t)=w¯eλt,(41) where u¯ and w¯ are arbitrary constants, v¯(x) is an x-depending function and λ is a complex number. Substituting (Equation41) into (Equation40) yields (42) λu¯=gu¯rM0x0v¯(x)dx+20x0xx0b(y)f(x,y)v¯(y)dydxλv¯(x)=rM0dv¯dx(x)(m(x)+b(x))v¯(x)+2xb(y)f(x,y)v¯(y)dyλ=k0.(42) One eigenvalue of (Equation42) is λ=k0<0. The remaining eigenvalues will be derived later. Using the second equation in (Equation42), we have (43) 2xb(y)f(x,y)v¯(y)dy=rM0dv¯dx(x)+(λ+m(x)+b(x))v¯(x)(43) and the first equation in (Equation42) is equivalent to (44) λu¯=gu¯rM0x0v¯(x)dx+20x0xx0xb(y)f(x,y)v¯(y)dydx+20x0xxb(y)f(x,y)v¯(y)dy.(44) Substituting (Equation43) into (Equation44) reduces the latter to λ=(g+(rM0/u¯)x0v¯(x)dx)<0. It follows that the spectral bound of (Equation42) is negative and hence, the following result is stated.

Theorem 5.1

The disease-free steady state E0 is stable.

Likewise, by considering the disease steady state E, we define the functions u, v(x,) and w by u(t)=M(t)M,v(x,t)=p(x,t)p(x),w(t)=D(t) and we obtain the following system (45) dudt(t)=(g+rP)u(t)rMx0v(x,t)dx+20x0xx0b(y)f(x,y)v(y,t)dydxvt(x,t)=rMvx(x,t)(m(x)+b(x))v(x,t)+2xb(y)f(x,y)v(y,t)dyru(t)dpdx(x)k2w(t)p(x)dwdt(t)=k0w(t)+k1w(t)P.(45) To derive the characteristic equations of the system (Equation45), the functions u, v(x,) and w defined in (Equation41) are used into (Equation45) so that (46) λu¯=(g+rP)u¯rMx0v¯(x)dx+20x0xx0b(y)f(x,y)v¯(y)dydxλv¯(x)=rMdv¯dx(x)(m(x)+b(x))v¯(x)+2xb(y)f(x,y)v¯(y)dyru¯dpdx(x)k2w¯p(x)λ=k0+k1P.(46) One eigenvalue of (Equation46) is λ=k0+k1P, which is negative if P<k0/k1 and positive if P>k0/k1. The remaining eigenvalues will be derived later. Using the second equation in (Equation46), we have (47) 2xb(y)f(x,y)v¯(y)dy=rMdv¯dx(x)+(λ+m(x)+b(x))v¯(x)+ru¯dpdx(x)+k2w¯p(x)(47) and the first equation in (Equation46) is equivalent to (48) λu¯=(g+rP)u¯rMx0v¯(x)dx+20x0xx0xb(y)f(x,y)v¯(y)dydx+20x0xxb(y)f(x,y)v¯(y)dy.(48) Substituting (Equation47) into (Equation48) reduces the latter to λ=(g+rP+(rM/u¯)x0v¯(x)dx)<0. It follows that the spectral bound of (Equation46) is negative if P<k0/k1. Hence, we have the following result.

Theorem 5.2

The disease steady state E is locally asymptotically stable if P<k0/k1 and unstable if P>k0/k1.

In a similar way, by considering the coexistence steady state E˘, we define the functions u, v(x,) and w by u(t)=M(t)M˘,v(x,t)=p(x,t)p˘(x),w(t)=D(t)D˘ and we obtain the following system (49) dudt(t)=(g+rk0k1)u(t)rM˘x0v(x,t)dx+20x0xx0b(y)f(x,y)v(y,t)dydxvt(x,t)=rM˘vx(x,t)(m(x)+b(x)+k2D˘)v(x,t)+2xb(y)f(x,y)v(y,t)dyru(t)dp˘dx(x)k2w(t)p˘(x)dwdt(t)=k1D˘x0v(x,t)dx.(49) To derive the characteristic equations of the system (Equation49), the functions u, v(x,) and w defined in (Equation41) are used into (Equation49) so that (50) λu¯=(g+rk0k1)u¯rM˘x0v¯(x)dx+20x0xx0b(y)f(x,y)v¯(y)dydxλv¯(x)=rM˘dv¯dx(x)(m(x)+b(x)+k2D˘)v¯(x)+2xb(y)f(x,y)v¯(y)dyru¯dp˘dx(x)k2w¯p˘(x)λ=k1w¯x0v¯(x)dx.(50) From the last equation in (Equation50), it follows that the spectral bound of (Equation50) is positive and hence, and then we have the result below.

Theorem 5.3

The coexistence steady state E˘ is unstable if it exists.

6. Global stability of equilibria

This section focuses on the global asymptotic stability analysis of the system (Equation1) at the equilibria E0 and E. This is achieved by means of appropriate Volterra-type functions of the form G(X)=X1lnX and the following result are obtained.

Theorem 6.1

The disease-free steady state E0 is globally asymptotically stable.

Proof.

We consider the Lyapunov function L0(t)=L10(t)+L20(t), where L10(t)=M0G(M(t)/M0),L20(t)=D(t)+Q(t). Differentiating L10(t), making use of the first equation in (Equation1) and A=gM0 and changing the order of integration, we have (51) dL10dt(t)=gM0(2M0M(t)M(t)M0)+rM0(1M(t)M0)P(t)+(1M0M(t))x0(20x0xf(x,y)dx)b(y)p(y,t)dy.(51) We now differentiate L20(t), make use of the second and last equations in (Equation1) and change the order of integration so that (52) dL20dt=k0D+(k1D+rM)Px0x(m(x)+b(x)+k2D)p(x,)dx+x0(2x0yxf(x,y)dx)b(y)p(y,)dy.(52) Combining (Equation51) and (Equation52) and using (Equation9), of A3, we get (53) dL0dt=k0D+gM0(2M0MMM0)+(rM0Px0x(m(x)p(x,)dx)+(k1Pk2Q)DM0Mx0(20x0xf(x,y)dx)b(y)p(y,)dy.(53) Clearly, the first, second and last terms in (Equation53) are negative. Using assumption A1 and condition (Equation4), we get (54) (k1P(t)k2Q(t))D(t)=k1D(t)Q(t)(P(t)Q(t)1)<0(54) and by assumption A2 and condition (Equation4), we obtain (55) rM0P(t)x0xm(x)p(x,t)dxrM0Q(t)(P(t)Q(t)1)<0.(55) Hence, dL0/dt<0 is satisfied for any M(t),p(x,t),D(t)R+ and dL0/dt=0 for (M(t),p(x,t),D(t))=(M0,p0(x),D0). Furthermore, it can be verified that {(M(t),p(x,t),D(t)):L˙0(t)=0}={E0}. Therefore, it follows from Lasalle's Invariance Theorem [Citation1, p. 200] that E0 is globally asymptotically stable.

Theorem 6.2

The disease steady state E is globally asymptotically stable if P<k0/k1.

Proof.

We consider the Lyapunov function L(t)=L1+L2(t), where L1(t)=MG(M(t)/M),L2(t)=D(t)+x0p(x)G(p(x,t)/p(x))dx. Differentiating L1(t) and then making use of the first equation in (Equation1) and substituting A by the following expression A=(g+rP)M20x0xx0b(y)f(x,y)p(y)dydx and changing the order of integration, we obtain dL1dt=(MM)2M(g+rP)rMx0p(x)(1MM)(1p(x)p(x,))dx+x0(20x0xf(x,y)dx)(1MM)(1p(y)p(y,))b(y)p(y,t)dy We now differentiate L2(t), make use of the second and the last equations in (Equation1) and rM(dp/dx)(x)(m(x)+b(x))p(x)+2xb(y)f(x,y)p(y)dy=0 and change the order of integration so that dL2dt(t)=(k0k1P)D(t)(k2k1)D(t)x0(1p(x)p(x,t))p(x,t)dx+rMx0(1p(x)p(x,t))dpdx(x)dxrM(t)x0(1p(x)p(x,t))px(x,t)dxx0(m(x)+b(x))p(x,t)(1p(x)p(x,t))2dx+2x0(x0y(1p(x)p(x,t))f(x,y)dx)(1p(y)p(y,t))b(y)p(y,t)dy. Expanding terms in the latter equation and making use of conditions p(x0,t)=p(x0)=0 and limxp(x,t)=limxp(x)=0, we get (56) dL2dt=k1(k0k1P)Dk2(1k1k2)Dx0(1p(x)p(x,))p(x,)dxx0(MMlnp(x,t)+p(x)p(x,))(rMdpdx(x))dxx0(m(x)+b(x))p(x,)(1p(x)p(x,t))2dx+2x0(x0y(1p(x)p(x,))f(x,y)dx)(1p(y)p(y,))b(y)p(y,)dy.(56) Using rM(dp/dx)(x)=(m(x)+b(x))p(x)2xb(y)f(x,y)p(y)dy in Equation (Equation56) yields dL2dt(t)=k1(k0k1P)D(t)k2(1k1k2)D(t)x0(1p(x)p(x,t))p(x,t)dx+x0(m(x)+b(x))(MMlnp(x,t)+p(x)p(x,t))p(x)dx2x0(MMlnp(x,t)+p(x)p(x,t))xf(x,y)b(y)p(y)dydxx0(m(x)+b(x))p(x,t)(1p(x)p(x,t))2dx+2x0(x0y(1p(x)p(x,t))f(x,y)dx)(1p(y)p(y,t))b(y)p(y,t)dy and therefore, we obtain (57) dLdt(t)=(M(t)M)2M(t)(g+rP)k1(k0k1P)D(t)k2(1k1k2)D(t)x0(1p(x)p(x,t))p(x,t)dxrM(t)x0(1MM(t))(1p(x)p(x,t))p(x)dx+x0(m(x)+b(x))(M(t)Mlnp(x,t)+p(x)p(x,t))p(x)dx2x0(M(t)Mlnp(x,t)+p(x)p(x,t))xf(x,y)b(y)p(y)dydxx0(m(x)+b(x))(1p(x)p(x,t))2p(x,t)dx+x0(20x0xf(x,y)dx)(1MM(t))(1p(y)p(y,t))b(y)p(y,t)dy+x0(2x0y(1p(x)p(x,t))f(x,y)dx)(1p(y)p(y,t))b(y)p(y,t)dy.(57) From the right-hand side in (Equation57), we clearly see that the first term is negative, the second term is also negative since P<k0/k1 and the third term vanishes by assumption A1. Most of the remaining terms on the right-hand side in (Equation57) will be expanded in the following manner. The fourth term in (Equation57) becomes (58) rM(t)x0(1MM(t))(1p(x)p(x,t))p(x)dx=rM(t)x0(1MM(t))p(x)dx+rM(t)x0(1MM(t))(p(x)p(x,t))2p(x,t)dx.(58) The fifth term in (Equation57) is expanded as (59) x0(m(x)+b(x))(M(t)Mlnp(x,t)+p(x)p(x,t))p(x)dx=M(t)Mx0(m(x)+b(x))(lnp(x,t)p(x,t))p(x)dx+x0(m(x)+b(x))(M(t)Mp(x,t)+p(x)p(x,t))p(x)dx,(59) where the first term on the right-hand side in (Equation59) is negative. Next, we transform the sixth term in (Equation57) into (60) 2x0(M(t)Mlnp(x,t)+p(x)p(x,t))xf(x,y)b(y)p(y)dydx=M(t)Mx02(lnp(x,t)+p(x,t))xf(x,y)b(y)p(y)dydx+x02(x0y(M(t)Mp(x,t)p(x)p(x,t))f(x,y)dx)b(y)p(y)dy,(60) where the first term on the right-hand side in (Equation60) is negative. We also expand the seventh term in (Equation57) as (61) x0(m(x)+b(x))(1p(x)p(x,t))2p(x,t)dx=x0(m(x)+b(x))[1+2p(x)p(x,t)(p(x)p(x,t))2]p(x,t)dx.(61) The eighth term in (Equation57) yields (62) x0(20x0xf(x,y)dx)(1MM(t))(1p(y)p(y,t))b(y)p(y,t)dy=x0(20x0xf(x,y)dx)(1MM(t))b(y)p(y,t)dyx0(20x0xf(x,y)dx)(1MM(t))b(y)p(y)dy.(62) Finally, we transform the last term in (Equation57) into (63) x0(2x0y(1p(x)p(x,t))f(x,y)dx)(1p(y)p(y,t))b(y)p(y,t)dy=x0(2x0y(1p(x)p(x,t))f(x,y)dx)b(y)p(y,t)dyx0(2x0y(1p(x)p(x,t))f(x,y)dx)b(y)p(y)dy.(63) By adding up the last terms in Equations (Equation60) and (Equation63), it follows that (64) x02(x0y(M(t)Mp(x,t)p(x)p(x,t))f(x,y)dx)b(y)p(y)dyx0(2x0y(1p(x)p(x,t))f(x,y)dx)b(y)p(y)dy=2x0(x0y(1M(t)Mp(x,t))f(x,y)dx)b(y)p(y)dy,(64) which is negative provided that p(x,t)<M/M(t) for any t0 and x>x0. In the sequel, we shall investigate the sign of the remaing terms under the conditions p(x,t)<M/M(t)<1 and 1<p(x,t)<M/M(t).

First, we assume that p(x,t)<M/M(t)<1. We clearly see in Equation (Equation58) that the first term on right-hand side is negative, while the second term can be expanded as (65) rM(t)x0(1MM(t))(p(x)p(x,t))2p(x,t)dx=rM(t)x0(p(x)p(x,t))2p(x,t)dxrMx0(p(x)p(x,t))2p(x,t)dx,(65) where the second term on the right-hand side is negative, and the first term on the right-hand side in Equation (Equation63) can be expanded as (66) x0(2x0y(1p(x)p(x,t))f(x,y)dx)b(y)p(y,t)dy=x0(2x0yf(x,y)dx)b(y)p(y,t)dyx0(2x0yp(x)p(x,t)f(x,y)dx)b(y)p(y,t)dy,(66) where the second term on the right-hand side is negative. Adding up the second term on the right hand side in (Equation65) and the first term on the right-hand side in (Equation66), we have rMx0(p(x)p(x,t))2p(x,t)dx+x0(2x0yf(x,y)dx)b(y)p(y,t)dyx0m(x)(1rMm(x)p(x)p(x,t))(1+rMm(x)p(x)p(x,t))p(x,t)dx<0, provided that 1<m(x)/rM<p(x)/p(x,t) for any t0 and x>x0. Moreover, the second term on the right-hand side in (Equation59), Equation (Equation61), the first term on the right-hand side in (Equation62) and the first term on the right-hand side in (Equation65) yields (67) x0(m(x)+b(x))(M(t)Mp(x,t)+p(x)p(x,t))p(x)dx+x0(m(x)+b(x))(1+2p(x)p(x,t)(p(x)p(x,t))2)p(x,t)dx+x0(20x0xf(x,y)dx)(1MM(t))b(y)p(y,t)dy+rM(t)x0(p(x)p(x,t))2p(x,t)dxx0[(m(x)+b(x))(3p(x)p(x,t)MM(t))+rM(t)(p(x)p(x,t))2]p(x,t)dx,(67) since p(x,t)<M/M(t). It is not difficult to show that rM(t)(p(x)p(x,t))2+3(m(x)+b(x))p(x)p(x,t)(m(x)+b(x))MM(t)<0 if p(x)/p(x,t)<m(x)+b(x)rM/rM, that is p(x)/p(x,t)<m(x)+b(x) for any t0 and x>x0. Therefore m(x)/rM<p(x)/p(x,t)<m(x)+b(x) and hence, dL/dt<0 is satisfied for (M(t),p(x,t),D(t)) such that p(x,t)<MM(t)<1,1<m(x)rM<p(x)p(x,t)<m(x)+b(x),D(t)R+ and dL/dt=0 for (M(t),p(x,t),D(t))=(M,p(x),D).

Finally, we assume that 1<p(x,t)<M/M(t). It follows that the second term on the right-hand side in (Equation58) and the first term on the right-hand side in (Equation62) are both negative, while the remaining terms on the right-hand side in (Equation58) and (Equation62) can be transformed, respectively, as follows (68) rM(t)x0(1MM(t))p(x)dx=rPM(t)+x0rMp(x)p(x,t)p(x,t)dx(68) and (69) x0(20x0xf(x,y)dx)(1MM(t))b(y)p(y)dyx0yb(y)p(y)dy+x0MM(t)yb(y)p(y)dy,(69) where the first terms on the right-hand side in (Equation68) and (Equation69) are negative. After using A2, the second terms in (Equation68) and (Equation69) yield, respectively, (70) x0rMp(x)p(x,t)p(x,t)dx<x0m(x)p(x)p(x,t)p(x,t)dx(70) and (71) x0MM(t)yb(y)p(y)dy<x0MM(t)m(y)p(y)dy.(71) The first term on the right-hand side in (Equation63) can also be transformed into (72) x0(2x0y(1p(x)p(x,t))f(x,y)dx)b(y)p(y,t)dyx02b(y)p(y,t)dyx0(2x0y(p(x)p(x,t))f(x,y)dx)b(y)p(y,t)dy,(72) where the second term on the right-hand side is negative, while the first term on the right-hand side yields (73) x02b(y)p(y,t)dy<x0m(y)p(y,t)dy.(73) From (Equation71) and (Equation73), we get (74) x0MM(t)yb(y)p(y)dy+x02b(y)p(y,t)dy<x0[MM(t)+12(MM(t))2+12(p(y)p(y,t))2]m(y)p(y,t)dy.(74) Combining the second term on the right-hand side in (Equation59)–(Equation61), (Equation70) and (Equation74), we obtain (75) x0(m(x)+b(x))(1p(x)p(x,t))2p(x,t)dx+x0(m(x)+b(x))(M(t)Mp(x,t)+p(x)p(x,t))p(x)dx+x0MM(t)yb(y)p(y)dy+x02b(y)p(y,t)dy+x0rMp(x)p(x,t)p(x,t)dx<x0(m(x)+b(x))[1+3p(x)p(x,t)+M(t)Mp(x)+MM(t)+12(MM(t))2+12(p(y)p(y,t))2]p(x,t)dx<x0(m(x)+b(x))[1+4p(x)+MM(t)+12(MM(t))2+12(p(y)p(y,t))2]×p(x,t)dx,<x0(m(x)+b(x))[1+4p(x)+p(x)2+MM(t)+12(MM(t))2]p(x,t)dx,(75) since 1<p(x,t)<M/M(t). Writing the integrand in (Equation75) as (76) 1+4p(x)+p(x)2+MM(t)+12(MM(t))2=12[(p(x)+4)2+(MM(t)+1)219],(76) it is not difficult to see that (Equation76) is negative provided that (77) (p(x)+4)2+(MM(t)+1)2<(19)2,(77) for any t0 and x>x0, that is p(x)+4<19 and M/M(t)+1<19, and then (78) p(x)<925<1andMM(t)<175<4.(78) Since 1<p(x,t)<M/M(t), thus 0<px)/p(x,t)<1 and 1<M/M(t)<4. Hence, dL/dt<0 is satisfied for (M(t),p(x,t),D(t)) such that 1<p(x,t)<MM(t)<175<4,0<px)p(x,t)<925<1,D(t)R+ and dL/dt=0 for (M(t),p(x,t),D(t))=(M,p(x),D).

In summary, dL/dt<0 if (M(t),p(x,t),D(t)) satisfies either of the following cases:

  1. p(x,t)<M/M(t)<1,1<m(x)/rM<p(x)/p(x,t)<m(x)+b(x),D(t)R+

  2. 1<p(x,t)<M/M(t)<175<4,0<px)/p(x,t)<925<1,D(t)R+

and dL/dt=0 for (M(t),p(x,t),D(t))=(M,p(x),D). Furthermore, it can be verified that {(M(t),p(x,t),D(t)):L˙(t)=0}={E}. Therefore, it follows from Lasalle's Invariance Theorem [Citation1, p. 200] that E is globally asymptotically stable if P<k0/k1.

7. Discussions

Let C0 be a parameter defined by C0=(k1/k0)P. Since, from the results of Theorems 5.2 and 6.2, the disease state equilibrium E is stable if C0<1 and unstable if C0>1 and the (unstable) coexistence state equilibrium E˘ exists if C0=1, thus C0 can be regarded as an essential threshold parameter in the steady state and stability analysis for the dynamics of amyloid fibril formation defined by the system of equations (Equation1). Often, such a parameter can play a crucial role in implementing therapeutic interventions strategies. Clearly, C00 as P0, that is the development of T2DM disease is stable if the total population of polymers, P, is unsignificant, and C0 as P, that is the development of T2DM is unstable if the total population of polymers, P, is extremely high. Moreover, C0 as k00, that is the development of T2DM disease cannot stabilize if k0 is negligible, and C00 as k0, that is development of T2DM disease stabilizes if k0 is extremely large. However, the following C0k0=k1k02P=C0k0<0 shows that increasing the rate at which the drug is degraded from the system due to metabolic processes, k0, result in a beneficial impact on the control of amyloid fibril formation, that is, rising of k0 brakes the development of T2DM disease. Therefore, k0 is substantial parameter in elaborating an efficient therapeutic strategy aiming at controlling and stopping the development of T2DM disease.

Disclosure statement

No potential conflict of interest was reported by the author(s).

References

  • P. Auger, R. Bravo de la Parra , J.-C. Poggiale, E. Sánchez, and T. Nguyen-Huu, Aggregation of variables and applications to population dynamics, in Structured Population Models in Biology and Epidemiology, P. Magal and S. Ruan, eds., Lecture Notes in Mathematics, Springer, Berlin, 2008, pp. 209–263.
  • A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, and P.C. Butler, Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes, Diabetes 52 (2003), pp. 102–110. doi: 10.2337/diabetes.52.1.102
  • J. Folch, M. Ettcheto, O. Busquets, E. Sánchez-López, R.D. Castro-Torres, E. Verdaguer, P.R. Manzine, S.R. Poor, M.L. García, J. Olloquequi, C. Beas-Zarate, C. Auladell, and A. Camins, The implication of the brain insulin reception in late onset Alzheimer's disease, Pharmaceuticals 11 (2018), pp. 1–16. doi: 10.3390/ph11010011
  • L. Haataja, T. Gurlo, C.J. Huang, and P.C. Butler, Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis, Endocr. Rev. 29 (2008), pp. 303–316. doi: 10.1210/er.2007-0037
  • J.K. Hale, Asymptotic behavior of dissipative systems, Mathematical Surveys and Monographs Vol. 25, Amer. Math. Soc., Providence, RI, 1988.
  • M.R. Hayden, S.C. Tyagi, M.M. Kerklo, and M.R. Nicolls, Type 2 diabetes mellitus as conformational disease, J. Pancreas 6 (2005), pp. 287–302.
  • M.R. Hayden and J.R. Sowers, Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome, J. Am. Soc. Hypertens. 2 (2008), pp. 239–266. doi: 10.1016/j.jash.2007.12.002
  • J.W.M. Hoppener and C.J.M. Lips, Role of islet amyloid in type 2 diabetes mellitus, Int. J. Biochem. Cell Biol. 38 (2006), pp. 726–736. doi: 10.1016/j.biocel.2005.12.009
  • R.L. Hull, Z.P. Shen, M.R. Watts, K. Kodama, D.B. Carr, K.M. Utzschneider, S. Zraika, F. Wang, and S.E. Kahn, Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide, Diabetes 54 (2005), pp. 2235–2244. doi: 10.2337/diabetes.54.7.2235
  • R.L. Hull, G.T. Westermark, P. Westermark, and S.E. Kahn, Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes, J. Clin. Endocrinol. Metab. 89 (2004), pp. 3629–3643. doi: 10.1210/jc.2004-0405
  • O.H.M. Ibrahim and M.A. Hassan, The use of anti-diabetic drugs in Alzheimer's disease, new therapeutic options and future perspective, Pharmacol. Pharm. 9 (2018), pp. 157–174. doi: 10.4236/pp.2018.96013
  • H.J. Kim, K.-A. Chang, T.-Y. Ha, J. Kim, S. Ha, K.-Y. Shin, C. Moon, W. Nacken, H.-S. Kim, and Y.-H. Suh, S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model, PLoS One 9 (2014), pp. 1–9.
  • R.Y. M'pika Massoukou, S.C. Oukouomi Noutchie, and R. Guiem, Global dynamics of an SVEIR model with age-dependent vaccination, infection, and latency, Abst. Appl. Anal. 2018 (2018), pp. 1–21. doi: 10.1155/2018/8479638
  • Z. Ma and G.T. Westermark, Effects of free fatty acid on polymerization of islet amyloid polypeptide (IAPP) in vitro and on amyloid fibril formation in cultivated isolated islets of transgenic mice overexpressing human IAPP, Mol. Med. 8 (2002), pp. 863–868. doi: 10.1007/BF03402092
  • P. Murali and M. Raman, Modeling the dynamics of amyloid formation of islet beta cells under therapeutic interventions and its role in discovery of novel target for drug action, Int. J. Life Sci. Med. Res. 3 (2013), pp. 1–10. doi: 10.5963/LSMR0301001
  • E. Rhoades and A. Gafni, Micelle formation by a fragment of human islet amyloid polypeptide, Biophys. J. 84 (2003), pp. 3480–3487. doi: 10.1016/S0006-3495(03)70068-X
  • G. Simonett and C. Walker, On the solvability of a mathematical model for prion proliferation, J. Math. Anal. Appl. 324 (2006), pp. 580–603. doi: 10.1016/j.jmaa.2005.12.036
  • H.L. Smith and H.R. Thieme, Dynamical systems and population persistence, Graduate Studies in Mathematics Vol. 118, Amer. Math. Soc., Providence, RI, 2011.
  • C. Walker, Prion proliferation with unbounded polymerization rates, Elect. J. Diff. Equ. Conf. 15 (2007), pp. 387–397.
  • G.F. Webb, Theory of Non-linear Age-Dependent Population Dynamics Vol. 89, Marcel Dekker, New York, 89, 1985.
  • P. Westermark, U. Engstrom, K. H.Johnson, G.T. Westermark, and C. Betsholtz, Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation, Proc. Natl. Acad. Sci. 87 (1990), pp. 5036–5040. doi: 10.1073/pnas.87.13.5036